What clinical trial milestone did Telix Pharmaceuticals (ASX:TLX) just achieve?

Telix Pharmaceuticals has completed patient enrolment for its Phase 1 IPAX-2 clinical trial. This international, multicentre study is evaluating the company's targeted radiopharmaceutical candidate, TLX101-Tx, in 12 patients with newly diagnosed glioblastoma.

What is TLX101-Tx, and what disease does it target?

TLX101-Tx is a targeted radiopharmaceutical therapy being developed by Telix Pharmaceuticals to treat glioblastoma, an aggressive and fast-growing form of brain cancer. The drug is designed to deliver targeted radiation directly to cancer cells, specifically aiming to improve outcomes for patients undergoing initial and subsequent lines of treatment.

What were the safety and toxicity results from the Telix Pharmaceuticals (ASX:TLX) IPAX-2 trial?

No dose-limiting toxicities (DLTs) have been observed in the trial to date. This safety profile holds true even at the highest evaluated dosage of 10GBq, which was administered to patients across two separate 5GBq treatments.

How was the Phase 1 IPAX-2 trial for Telix Pharmaceuticals structured?

The open-label, dose-finding trial enrolled 12 patients divided into three dose-escalating cohorts across four clinical sites in Australia, Austria, and the Netherlands.

What is the investment thesis for Telix Pharmaceuticals (ASX:TLX) regarding its glioblastoma pipeline?

The investment thesis hinges on Telix successfully commercialising the first-ever radiopharmaceutical therapy for glioblastoma, a multi-billion dollar market with high unmet medical needs.

What are the main bull and bear points for Telix Pharmaceuticals (ASX:TLX) after this news?

The bull case is that zero dose-limiting toxicities at maximum dosage validates the drug's safety profile and clears the path for advanced clinical development. The bear case is that Phase 1 trials only establish safety, meaning retail investors still face years of clinical, regulatory, and commercialisation risks before the drug generates revenue.

Image for illustrative purposes only. Not a real photo.

Telix Pharmaceuticals completes enrolment for glioblastoma trial

Written by Liezl GambePublished May. 18 2026Last Updated May. 18 2026

Australian radiopharmaceutical company Telix Pharmaceuticals (ASX:TLX) completed patient enrolment for its international, multicentre Phase 1 IPAX-2 clinical trial.

The study is evaluating TLX101-Tx (131I-iodofalan) in patients with newly diagnosed glioblastoma, an aggressive form of brain cancer.

No dose-limiting toxicities have been observed to date, even at the study's maximum administered dose of 10GBq, delivered across two 5GBq treatments.

The open-label trial enrolled 12 patients across three dose-escalating cohorts located in Australia, Austria, and the Netherlands.

The study aims to evaluate the safety, tolerability, and maximum tolerated dose of the therapy when combined with standard post-surgical treatments, including radiation and chemotherapy.

Dr David N. Cade, Telix’s Group Chief Medical Officer, expressed optimism regarding the milestone, noting that the excellent tolerability profile strongly supports the ongoing development of this targeted candidate.

Patients will continue their standard-of-care regimen until the study's conclusion, at which point the primary endpoint will be confirmed.

Telix is advancing its pivotal Phase 3 IPAX BrIGHT trial, which marks a historic milestone as the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma.

The larger study evaluates TLX101-Tx in patients with recurrent disease.

Throughout these trials, Telix is utilising its companion PET imaging agent, TLX101-Px, to identify eligible patients with overexpressed LAT1 proteins and monitor tumour response.